GeneDx Holdings (WGS) Share-based Compensation (2020 - 2026)
GeneDx Holdings has reported Share-based Compensation over the past 7 years, most recently at $9.0 million for Q1 2026.
- Quarterly Share-based Compensation rose 125.86% to $9.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $37.2 million through Mar 2026, up 173.91% year-over-year, with the annual reading at $32.2 million for FY2025, 251.96% up from the prior year.
- Share-based Compensation was $9.0 million for Q1 2026 at GeneDx Holdings, down from $9.8 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $22.7 million in Q2 2022 and troughed at -$912000.0 in Q4 2023.
- The 5-year median for Share-based Compensation is $3.1 million (2024), against an average of $5.4 million.
- Year-over-year, Share-based Compensation soared 4477.84% in 2022 and then plummeted 1039.58% in 2024.
- A 5-year view of Share-based Compensation shows it stood at $422000.0 in 2022, then tumbled by 316.11% to -$912000.0 in 2023, then soared by 411.95% to $2.8 million in 2024, then soared by 243.76% to $9.8 million in 2025, then fell by 8.02% to $9.0 million in 2026.
- Per Business Quant, the three most recent readings for WGS's Share-based Compensation are $9.0 million (Q1 2026), $9.8 million (Q4 2025), and $10.6 million (Q3 2025).